Asceneuron aims to address high unmet medical needs in neurodegenerative proteinopathies such as orphan tauopathies, Alzheimer’s and Parkinson’s disease. Our pipeline is composed of innovative small-molecule therapeutics aiming to prevent disease progression in proteinopathies and reverse cognitive impairment in dementia.
* Partenered with Ferrer 
AD: Alzheimer's disease
LBD: Lewy Body Dementia
FTD: Frontotemporal dementia
PDD: Parkinson's disease dementia
PSP: Progressive Supranuclear Palsy
About ASN90
ASN90 (formerly labelled as ASN120290 or ASN-561) is an in-house developed OGA inhibitor which has been outlicensed to our partner Ferrer for the orphan tau-related disease, progressive supranuclear palsy (PSP).
ASN90 received orphan drug designations by the US FDA and the European EMA for the treatment of PSP. The molecule has completed three clinical studies in healthy volunteers including a randomized, double-blind, placebo-controlled phase I study to assess its safety and tolerability of single and multiple doses in healthy young and elderly volunteers and a human positron emission tomography (PET) CNS target engagement study.
Asceneuron is exploring further potential indications for ASN90.
About ASN51
Asceneuron’s next generation OGA inhibitor ASN51 has been awarded USD 2.2 million from the Alzheimer’s Drug Discovery Foundation for a first in human Phase I study.
ASN51 has completed two clinical studies in healthy volunteers including a randomized, double-blind, placebo-controlled phase I study to assess its safety and tolerability of single and multiple doses in healthy young and elderly volunteers and a human positron emission tomography (PET) CNS target engagement study.
A multiple ascending dose PET study is currently ongoing, to investigate the brain occupancy of O-GlcNAcase, and the pharmacodynamic response in peripheral blood mononuclear cells, after repeated doses of ASN51 to healthy subjects.
